Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.59 |
| ▸ | ACE | P12821 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ECE1 | P42892 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29576224 | 0.99 | MME (0.60) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL10598700 | 0.90 | FNTA (0.56) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL29350735 | 0.89 | OPRD1 (0.58) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL29453929 | 0.89 | FNTA (0.60) | — | |
| SCHEMBL29658873 | 0.88 | MME (0.60) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL29658943 | 0.88 | MME (0.60) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL14691645 | 0.87 | MME (0.51) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL27906371 | 0.87 | MME (0.51) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL31025582 | 0.87 | MME (0.62) | MMEACEMMP2 | |
| SCHEMBL31025651 | 0.87 | MME (0.62) | MMEACEMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12412749-B2 | Etching method and plasma processing system | TOKYO ELECTRON LIMITED (JP) | 2025-09-09 | — | — | US | claimed |
| US-20230307243-A1 | ETCHING METHOD AND PLASMA PROCESSING SYSTEM | TOKYO ELECTRON LIMITED (JP) | 2023-09-28 | — | — | US | claimed |
| CN-115408698-A | Rust vulnerability detection method based on rust-IR2Graph and RGNN | 内蒙古大学 | 2022-11-29 | — | — | CN | claimed |
| US-12412749-B2 | Etching method and plasma processing system | TOKYO ELECTRON LIMITED (JP) | 2025-09-09 | — | — | US | disclosed |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | UNIVERSITY OF WASHINGTON | 2025-04-03 | — | — | US | disclosed |
| US-20230307243-A1 | ETCHING METHOD AND PLASMA PROCESSING SYSTEM | TOKYO ELECTRON LIMITED (JP) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | DHFR, CCNH, ODC1 | MME 520/4885ACE 2373/4885ALDH1A1 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.